setrobuvir + danoprevir + ritonavir

**Setrobuvir + danoprevir + ritonavir** is an investigational oral combination regimen studied for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotype 1. Setrobuvir is a direct-acting antiviral (DAA) that acts as a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase (NS5B). Danoprevir is a macrocyclic inhibitor of the HCV NS3/4A serine protease, while ritonavir acts as a pharmacokinetic enhancer (booster) that increases danoprevir plasma concentrations by inhibiting CYP3A metabolism. The combination has been studied in interferon-free regimens, often together with ribavirin and/or mericitabine. Clinical studies have demonstrated efficacy (as measured by sustained virologic response rates) and an acceptable safety profile in treatment-naive patients with HCV genotype 1[1][2][4].